Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference.
Mr. Tornos said adoption of the robot remains strong, and the company plans to launch three Rosa indications in the next 18 months, according to a March 13 investing.com transcript.
Rosa, which has been Zimmer Biomet’s flagship total knee replacement robot, earned FDA approval for its shoulder application in 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
